Skip to main content
Journal ArticleOPEN ACCESS

Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study

  • Bazarbashi S
  • Alkhatib R
  • Aseafan M
  • et al.
JCO Global Oncology (2024) (10)
DOI: 10.1200/go.23.00461
0Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.
Get full text

Abstract

FTD/TPI, regorafenib, and chemotherapy rechallenge are third-line treatment options for metastatic colorectal cancer

Cite

CITATION STYLE

APA

Bazarbashi, S., Alkhatib, R., Aseafan, M., Tuleimat, Y., Abdel-Aziz, N., Mahrous, M., … Alghamdi, M. (2024). Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study. JCO Global Oncology, (10). https://doi.org/10.1200/go.23.00461

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free